

=> file .Biotech
=> s (somatostatin (2a) 5 (2a) receptor# or SSTR(w)5)
L1 766 (SOMATOSTATIN (2A) 5 (2A) RECEPTOR# OR SSTR(W) 5)

=> s l1 and (select? agonist)
L2 54 L1 AND (SELECT? AGONIST)

=> s l2 and (hyperlipid? or lipidem?)
L3 7 L2 AND (HYPERLIPID? OR LIPIDEM?)

=> s l2 and (triacylglycer? or glycerol or cholesterol)
L4 6 L2 AND (TRIACYLGLYCER? OR GLYCEROL OR CHOLESTEROL)

=> s l3 and l4
L5 5 L3 AND L4

=> d l5 1-5 bib ab

L5 ANSWER 1 OF 5 USPATFULL on STN
AN 2004:108115 USPATFULL
TI Pharmaceutical compositions which inhibit vascular proliferation and
method of use thereof
IN Dewitt, Michael Culler, Hopkinton, MA, UNITED STATES
Danesi, Romano, Livorno, ITALY
Bocci, Guido, Lucca, ITALY
Deltacca, Mario, Pisa, ITALY
PI US 2004082517 A1 20040429
AI US 2003-466152 A1 20031118 (10)
WO 2002-US1125 20020114
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 701
AB The present invention relates to a method of treating vascular
proliferation in a patient in need thereof. The method includes the step
of administering a therapeutically effective amount of a type-1
somatostatin agonist to said patient.

L5 ANSWER 2 OF 5 USPATFULL on STN
AN 2004:95280 USPATFULL
TI Somatostatin and somatostatin agonists for treating insulin
insensitivity and Syndrome X
IN Cawthorne, Michael Anthony, Horsham, UNITED KINGDOM
Liu, Yong-Ling, Buckingham, UNITED KINGDOM
Sennitt, Matthew V., Climping, UNITED KINGDOM
PI US 2004072734 A1 20040415
AI US 2003-369143 A1 20030218 (10)
RLI Division of Ser. No. US 2000-423578, filed on 23 Feb 2000, ABANDONED
Continuation of Ser. No. WO 1998-EP3000, filed on 13 May 1998, UNKNOWN
Continuation of Ser. No. US 1997-854943, filed on 13 May 1997, ABANDONED
DT Utility
FS APPLICATION
LREP FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1155
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method of treating insulin resistance
or Syndrome X. The method includes the step of administering a
therapeutically effective amount of a somatostatin or a somatostatin
agonist to said patient. The invention also includes pharmaceutical

compositions comprising a somatostatin or somatostatin agonist and the use of such products in the preparation of such compositions.

L5 ANSWER 3 OF 5 USPATFULL on STN
AN 2002:273372 USPATFULL
TI METHOD AND COMPOSITIONS FOR TREATING **HYPERLIPIDEMIA** AND OTHER
CONDITIONS
IN CAWTHORNE, MICHAEL ANTHONY, WEST SUSSEX, UNITED KINGDOM
LIU, YONG-LING, BUCKINGHAM, UNITED KINGDOM
SENNITT, MATTHEW V., W. SUSSEX, UNITED KINGDOM
PI US 2002151500 A1 20021017
AI US 2000-423683 A1 20000320 (9)
WO 1998-EP2998 19980513
DT Utility
FS APPLICATION
LREP BRIAN R MORRILL, BIOMEASURE INC, 27 MAPLE STREET, MILFORD, MA,
01757-3650
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 587

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method of treating **hyperlipidemia** and to reducing **triacylglycerols**, **glycerol** and **cholesterol** in a patient. The method includes the step of administering a therapeutically effective amount of a type-5 selective somatostatin agonist to said patient. A pharmaceutical composition comprises said agonist and such product is used in the preparation of the composition for use in treating **hyperlipidemia** or reducing **triacylglycerols**, **glycerol** and **cholesterol** in a patient's body.

L5 ANSWER 4 OF 5 USPATFULL on STN
AN 2002:78717 USPATFULL
TI METHOD OF TREATING INSULIN INSENSITIVITY AND SYNDROME X
IN CAWTHORNE, MICHAEL ANTHONY, HORSHAM, UNITED KINGDOM
LIU, YONG-LING, BUCKINGHAM, UNITED KINGDOM
SENNITT, MATTHEW V., CHIPSTEAD, UNITED KINGDOM
PI US 2002042374 A1 20020411
AI US 1998-76948 A1 19980513 (9)
PRAI US 1997-46373P 19970513 (60)
DT Utility
FS APPLICATION
LREP JOHN D CONWAY, BIOMEASURE INC, 27 MAPLE STREET, MILFORD, MA, 017573650
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1115

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method of treating insulin resistance or syndrome X in a patient. The method includes the step of administering a therapeutically effective amount of a somatostatin or a somatostatin agonist to said patient.

L5 ANSWER 5 OF 5 USPATFULL on STN
AN 1999:166969 USPATFULL
TI Method of treating **hyperlipidemia**
IN Cawthorne, Michael Anthony, Horsham, United Kingdom
Liu, Yong-Ling, Buckingham, United Kingdom
Sennitt, Matthew V., Chipstead, United Kingdom
PA Biomeasure, Incorporated, Milford, MA, United States (U.S. corporation)
PI US 6004928 19991221
AI US 1998-78111 19980513 (9)
PRAI US 1997-46346P 19970513 (60)
DT Utility

FS Granted
EXNAM Primary Examiner: Russel, Jeffrey E.
LREP Conway, John D.Fish & Richardson
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 584

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method of decreasing body weight in a patient. The method includes the step of administering a therapeutically effective amount of a type-5 selective somatostatin agonist to the patient.

=> s l5 and (treat? or lower?)

L6 5 L5 AND (TREAT? OR LOWER?)

=> s pharmaceut? composit? and (l3 or l4 or l6)

L7 4 PHARMACEUT? COMPOSIT? AND (L3 OR L4 OR L6)

=> d l7 1-4 bib ab

L7 ANSWER 1 OF 4 USPATFULL on STN

AN 2004:108115 USPATFULL

TI **Pharmaceutical compositions** which inhibit vascular proliferation and method of use thereof

IN Dewitt, Michael Culler, Hopkinton, MA, UNITED STATES

Danesi, Romano, Livorno, ITALY

Bocci, Guido, Lucca, ITALY

Deltacca, Mario, Pisa, ITALY

PI US 2004082517 A1 20040429

AI US 2003-466152 A1 20031118 (10)

WO 2002-US1125 20020114

DT Utility

FS APPLICATION

LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110

CLMN Number of Claims: 16

ECL Exemplary Claim: 1

DRWN 8 Drawing Page(s)

LN.CNT 701

AB The present invention relates to a method of **treating** vascular proliferation in a patient in need thereof. The method includes the step of administering a therapeutically effective amount of a type-1 somatostatin agonist to said patient.

L7 ANSWER 2 OF 4 USPATFULL on STN

AN 2004:95280 USPATFULL

TI Somatostatin and somatostatin agonists for **treating** insulin insensitivity and Syndrome X

IN Cawthorne, Michael Anthony, Horsham, UNITED KINGDOM

Liu, Yong-Ling, Buckingham, UNITED KINGDOM

Sennitt, Matthew V., Climping, UNITED KINGDOM

PI US 2004072734 A1 20040415

AI US 2003-369143 A1 20030218 (10)

RLI Division of Ser. No. US 2000-423578, filed on 23 Feb 2000, ABANDONED
Continuation of Ser. No. WO 1998-EP3000, filed on 13 May 1998, UNKNOWN
Continuation of Ser. No. US 1997-854943, filed on 13 May 1997, ABANDONED

DT Utility

FS APPLICATION

LREP FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110

CLMN Number of Claims: 35

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1155

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method of **treating** insulin

resistance or Syndrome X. The method includes the step of administering a therapeutically effective amount of a somatostatin or a somatostatin agonist to said patient. The invention also includes **pharmaceutical compositions** comprising a somatostatin or somatostatin agonist and the use of such products in the preparation of such compositions.

L7 ANSWER 3 OF 4 USPATFULL on STN
AN 2002:273372 USPATFULL
TI METHOD AND COMPOSITIONS FOR **TREATING HYPERLIPIDEMIA**
AND OTHER CONDITIONS
IN CAWTHORNE, MICHAEL ANTHONY, WEST SUSSEX, UNITED KINGDOM
LIU, YONG-LING, BUCKINGHAM, UNITED KINGDOM
SENNITT, MATTHEW V., W. SUSSEX, UNITED KINGDOM
PI US 2002151500 A1 20021017
AI US 2000-423683 A1 20000320 (9)
WO 1998-EP2998 19980513
DT Utility
FS APPLICATION
LREP BRIAN R MORRILL, BIOMEASURE INC, 27 MAPLE STREET, MILFORD, MA,
01757-3650
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 587

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method of **treating hyperlipidemia** and to reducing **triacylglycerols, glycerol and cholesterol** in a patient. The method includes the step of administering a therapeutically effective amount of a type-5 selective somatostatin agonist to said patient. A **pharmaceutical composition** comprises said agonist and such product is used in the preparation of the composition for use in **treating hyperlipidemia** or reducing **triacylglycerols, glycerol and cholesterol** in a patient's body.

L7 ANSWER 4 OF 4 USPATFULL on STN
AN 2002:251723 USPATFULL
TI Selective treatment of endothelial somatostatin receptors
IN Hsiang, York, Vancouver, CANADA
Buchan, Alison, Vancouver, CANADA
Levy, Julia G., Vancouver, CANADA
Margaron, Philippe Maria Clotaire, Burnaby, CANADA
PI US 2002137676 A1 20020926
AI US 2001-797779 A1 20010301 (9)
RLI Continuation-in-part of Ser. No. WO 1999-CA8800, filed on 1 Sep 1999,
UNKNOWN
PRAI CA 1998-2246791 19980901
DT Utility
FS APPLICATION
LREP MORRISON & FOERSTER LLP, 3811 VALLEY CENTRE DRIVE, SUITE 500, SAN DIEGO,
CA, 92130-2332
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 989

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides for the use of somatostatin receptor selective ligands (selective for SSTR1 or SSTR4) to treat human endothelial cells and to formulate medicaments for human use. The medicaments may for example be used to treat an angiogenic disease. In various embodiments, the angiogenic disease may for example be macular degeneration or a solid tumor. The SSTR1 or SSTR4 selective agonists may include the SSTR1 agonist (des-AA.sup.1,2,5 [DTrp.sup.8,IAamp.sup.9]SS).

=> dup rem l3
PROCESSING COMPLETED FOR L3
L8 6 DUP REM L3 (1 DUPLICATE REMOVED)

=> d l8 1-6 bib ab

L8 ANSWER 1 OF 6 USPATFULL on STN
AN 2004:108115 USPATFULL
TI Pharmaceutical compositions which inhibit vascular proliferation and
method of use thereof
IN Dewitt, Michael Culler, Hopkinton, MA, UNITED STATES
Danesi, Romano, Livorno, ITALY
Bocci, Guido, Lucca, ITALY
Deltacca, Mario, Pisa, ITALY
PI US 2004082517 A1 20040429
AI US 2003-466152 A1 20031118 (10)
WO 2002-US1125 20020114
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 701
AB The present invention relates to a method of treating vascular
proliferation in a patient in need thereof. The method includes the step
of administering a therapeutically effective amount of a type-1
somatostatin agonist to said patient.

L8 ANSWER 2 OF 6 USPATFULL on STN
AN 2004:95280 USPATFULL
TI Somatostatin and somatostatin agonists for treating insulin
insensitivity and Syndrome X
IN Cawthorne, Michael Anthony, Horsham, UNITED KINGDOM
Liu, Yong-Ling, Buckingham, UNITED KINGDOM
Sennitt, Matthew V., Climping, UNITED KINGDOM
PI US 2004072734 A1 20040415
AI US 2003-369143 A1 20030218 (10)
RLI Division of Ser. No. US 2000-423578, filed on 23 Feb 2000, ABANDONED
Continuation of Ser. No. WO 1998-EP3000, filed on 13 May 1998, UNKNOWN
Continuation of Ser. No. US 1997-854943, filed on 13 May 1997, ABANDONED
DT Utility
FS APPLICATION
LREP FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1155
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method of treating insulin resistance
or Syndrome X. The method includes the step of administering a
therapeutically effective amount of a somatostatin or a somatostatin
agonist to said patient. The invention also includes pharmaceutical
compositions comprising a somatostatin or somatostatin agonist and the
use of such products in the preparation of such compositions.

L8 ANSWER 3 OF 6 USPATFULL on STN DUPLICATE 1
AN 2002:78717 USPATFULL
TI METHOD OF TREATING INSULIN INSENSITIVITY AND SYNDROME X
IN CAWTHORNE, MICHAEL ANTHONY, HORSHAM, UNITED KINGDOM
LIU, YONG-LING, BUCKINGHAM, UNITED KINGDOM
SENNITT, MATTHEW V., CHIPSTEAD, UNITED KINGDOM
PI US 2002042374 A1 20020411

AI US 1998-76948 A1 19980513 (9)
 PRAI US 1997-46373P 19970513 (60)
 DT Utility
 FS APPLICATION
 LREP JOHN D CONWAY, BIOMEASURE INC, 27 MAPLE STREET, MILFORD, MA, 017573650
 CLMN Number of Claims: 30
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 1115
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention relates to a method of treating insulin resistance or syndrome X in a patient. The method includes the step of administering a therapeutically effective amount of a somatostatin or a somatostatin agonist to said patient.

L8 ANSWER 4 OF 6 USPATFULL on STN
 AN 2002:273372 USPATFULL
 TI METHOD AND COMPOSITIONS FOR TREATING **HYPERLIPIDEMIA** AND OTHER CONDITIONS
 IN CAWTHORNE, MICHAEL ANTHONY, WEST SUSSEX, UNITED KINGDOM
 LIU, YONG-LING, BUCKINGHAM, UNITED KINGDOM
 SENNITT, MATTHEW V., W. SUSSEX, UNITED KINGDOM
 PI US 2002151500 A1 20021017
 AI US 2000-423683 A1 20000320 (9)
 WO 1998-EP2998 19980513
 DT Utility
 FS APPLICATION
 LREP BRIAN R MORRILL, BIOMEASURE INC, 27 MAPLE STREET, MILFORD, MA, 01757-3650
 CLMN Number of Claims: 31
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 587
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention relates to a method of treating **hyperlipidemia** and to reducing triacylglycerols, glycerol and cholesterol in a patient. The method includes the step of administering a therapeutically effective amount of a type-5 selective somatostatin agonist to said patient. A pharmaceutical composition comprises said agonist and such product is used in the preparation of the composition for use in treating **hyperlipidemia** or reducing triacylglycerols, glycerol and cholesterol in a patient's body.

L8 ANSWER 5 OF 6 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
 AN 2002-361791 [39] WPIDS
 DNC C2002-102310
 TI New imidazolyl derivatives, useful as selective agonists/antagonists of somatostatin receptors for treating acromegaly, restenosis, Crohn's disease and systemic sclerosis.
 DC B03
 IN BIGG, D C H; GARCERA, M; GORDON, T D; MOINET, C P; MORGAN, B A; POITOUT, L F; THURIEAU, C A; BIGG, D
 PA (SCRC) SCRAS SOC CONSEILS RECH & APPL SCI
 CYC 95
 PI WO 2002010140 A2 20020207 (200239)* EN 369
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
 NL OA PT SD SE SL SZ TR TZ UG ZW
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM
 DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC
 LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE
 SG SI SK SL TJ TM TR TT TZ UA UG US VZ VN YU ZA ZW
 AU 2001079098 A 20020213 (200239)
 NO 2003000473 A 20030130 (200324)
 EP 1305294 A2 20030502 (200331) EN
 R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT

RO SE SI TR

KR 2003020960 A 20030310 (200349)
CN 1444566 A 20030924 (200382)

ADT WO 2002010140 A2 WO 2001-US23959 20010731; AU 2001079098 A AU 2001-79098
20010731; NO 2003000473 A WO 2001-US23959 20010731, NO 2003-473 20030130;
EP 1305294 A2 EP 2001-957342 20010731, WO 2001-US23959 20010731; KR
2003020960 A KR 2003-701501 20030130; CN 1444566 A CN 2001-813618 20010731
FDT AU 2001079098 A Based on WO 2002010140; EP 1305294 A2 Based on WO
2002010140

PRAI US 2000-222584P 20000801

AB WO 2002010140 A UPAB: 20020621

NOVELTY - Imidazolyl derivatives (I) or their racemic-diastereomeric-
mixtures and optical isomers, salts, or prodrugs are new.

DETAILED DESCRIPTION - Imidazolyl derivatives of formula (I) or their
racemic-diastereomeric-mixtures and optical isomers, salts, or prodrugs
are new.

R1 = H, (CH₂)_mCO(CH₂)mZ1, (CH₂)mZ1, (CH₂)mOZ1 or 0-6C-
alkylC(O)NH(CH₂)mZ1;

Z1 = optionally substituted moiety selected from e.g. 1-12C alkyl, a
group of formula e.g. (a), isoxazolyl or indolyl;

R2 = H or 1-6C alkyl;

R1+ R2 = taken together with the N atoms to which they are attached
form a compound of formula (Ia)-(Ic)

;

R3 = (CH₂)_mE(CH₂)mZ2;

E = O, S, CO, CO₂, NHC(O)O or a bond;

Z2 = e.g. H, (1-12C)alkyl, or an optionally substituted moiety
selected from e.g. phenyl;

R4 = H or (CH₂)_mA1;

A1 = C(=Y)-N(X1X2), C(=Y)X2, C(=NH)X2 or X2;

Y = O or S;

X1 = H, 1-12C alkyl, (CH₂)_mNH-1-6C alkyl or (CH₂)_m-N-di(1-6C) alkyl
or (CH₂)_maryl;

X2 = (CH₂)_mY1-X3 or optionally substituted (1-12C)alkyl;

Y1 = O, S, NH, C=O, (2-12C)alkenyl having one or more double bonds,
NHCO, CONH, NHCO₂(CH₂)_m C triple bond C, SO₂ or a bond;

X3 = H, optionally substituted moiety selected from e.g. 1-12C alkyl,
(CH₂)_mphenyl, or a group of formula e.g. (d):

NX1X2 = optionally substituted moiety selected from thiazolyl or a
group of formula e.g. (m) or (p):

;

Y2 = CHX4, NX4, CX4X4, O or S;

X4 = (CH₂)_mY3-X5;

Y3 = C(O), CO₂ or a bond;

X5 = e.g. OH, 1-12C alkyl, or an optionally substituted moiety
selected from e.g. aryl, CH(phenyl)₂, or a group of formula (t):

;

R5 = (1-12C)alkyl, (0-6C)alkylCOOZ5, (0-6C)alkylC(O)NH(CH₂)mZ3 or
optionally substituted aryl;

Z3 = e.g. amino, NHC(O)O(CH₂)_mphenyl, NHC(O)O(CH₂)_m-1-6C alkyl or an
optionally substituted moiety selected from e.g. imidazolyl;

R6 = H or 1-6C alkyl;

R7 = (1-12C)alkyl or (CH₂)mZ4;

Z4 = optionally substituted moiety selected from e.g. phenyl, or a
group of formula e.g. (v):

;

Z5 = H, 1-12C alkyl (CH₂)_maryl;

where an optionally substituted moiety is optionally substituted by
one or more e.g. Cl, (CH₂)_mphenyl-(X₆)_n, S-phenyl-(X₆)_n, S-(1-12C) alkyl,
O(CH₂)_mphenyl-(X₆)_n, (CH₂)_mC(O)O-1-6C alkyl, (CH₂)_mC(O)-1-6C alkyl,
O(CH₂)_m-NH₂, O(CH₂)_mNH-1-6C alkyl, O(CH₂)_m-N-di-((1-6C)alkyl) or 0-12C
alkyl-(X₆)_n;

X₆ = e.g. H, (CH₂)_mNH₂, (CH₂)_mNH(1-6C)alkyl, (CH₂)_mNH(1-6C) alkyl,
(CH₂)_mN-di-((1-6C)alkyl) or (CH₂)_mphenyl;

m = 0-6;

n = 1-5; and
with provisos.

The full definitions are given in the DEFINITIONS (Full Definitions) Field.

ACTIVITY - Osteopathic; vasotropic; antiinflammatory; cytostatic; antidiarrheic; dermatological; ophthalmological; immunomodulator; hypertensive; tranquilizer; antidiabetic; antilipemic; nephrotropic; antiulcer; immunosuppressive; antibacterial.

MECHANISM OF ACTION - Somatostatin receptor agonists; Somatostatin receptor antagonists (claimed).

An assay is described for assessing the affinity of compounds (I) for human somatostatin subtype receptors 1 to 5 (i.e. sst1, sst2, sst3, sst4 and sst5) by measuring the inhibition of (125)-Tyr11)SRIF-14 binding to CHO-K1 transfected cells, but no results are given.

USE - For treating acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison Syndrome, diarrhea, AIDS related diarrhea, chemotherapy related diarrhea, scleroderma, Irritable Bowel Syndrome, pancreatitis, small bowel obstruction, gastroesophageal reflux, duodenogastric reflux, Cushing's Syndrome, gonadotropinoma, hyperparathyroidism, Graves' Disease, diabetic neuropathy, Paget's disease, polycystic ovary disease, cancer, cancer cachexia, hypotension, postprandial hypotension, panic attacks, GH secreting adenomas or TSH secreting adenomas. For treating diabetes mellitus, hyperlipidemia, insulin insensitivity, Syndrome X, angiopathy, proliferative retinopathy, dawn phenomenon, nephropathy, peptic ulcers, enterocutaneous and pancreaticocutaneous fistula, Dumping syndrome, watery diarrhea syndrome, acute or chronic pancreatitis, gastrointestinal hormone secreting tumors, angiogenesis, inflammatory disorders, chronic allograft rejection, angioplasty, graft vessel bleeding or gastrointestinal bleeding. For inhibiting the proliferation of Helicobacter pylori.

ADVANTAGE - (I) are non-peptide, selective or potent somatostatin receptor ligands.

Dwg.0/0

L8 ANSWER 6 OF 6 USPATFULL on STN
AN 1999:166969 USPATFULL
TI Method of treating **hyperlipidemia**
IN Cawthorne, Michael Anthony, Horsham, United Kingdom
Liu, Yong-Ling, Buckingham, United Kingdom
Sennitt, Matthew V., Chipstead, United Kingdom
PA Biomeasure, Incorporated, Milford, MA, United States (U.S. corporation)
PI US 6004928 19991221
AI US 1998-78111 19980513 (9)
PRAI US 1997-46346P 19970513 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Russel, Jeffrey E.
LREP Conway, John D. Fish & Richardson
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 584
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method of decreasing body weight in a patient. The method includes the step of administering a therapeutically effective amount of a type-5 selective somatostatin agonist to the patient.

=> dup rem 14

PROCESSING COMPLETED FOR L4

L9 6 DUP REM L4 (0 DUPLICATES REMOVED)

=> d 19 1-6 bib ab

L9 ANSWER 1 OF 6 USPATFULL on STN
 AN 2004:108115 USPATFULL
 TI Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
 IN Dewitt, Michael Culler, Hopkinton, MA, UNITED STATES
 Danesi, Romano, Livorno, ITALY
 Bocci, Guido, Lucca, ITALY
 Deltacca, Mario, Pisa, ITALY
 PI US 2004082517 A1 20040429
 AI US 2003-466152 A1 20031118 (10)
 WO 2002-US1125 20020114
 DT Utility
 FS APPLICATION
 LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110
 CLMN Number of Claims: 16
 ECL Exemplary Claim: 1
 DRWN 8 Drawing Page(s)
 LN.CNT 701
 AB The present invention relates to a method of treating vascular proliferation in a patient in need thereof. The method includes the step of administering a therapeutically effective amount of a type-1 somatostatin agonist to said patient.

L9 ANSWER 2 OF 6 USPATFULL on STN
 AN 2004:95280 USPATFULL
 TI Somatostatin and somatostatin agonists for treating insulin insensitivity and Syndrome X
 IN Cawthorne, Michael Anthony, Horsham, UNITED KINGDOM
 Liu, Yong-Ling, Buckingham, UNITED KINGDOM
 Sennitt, Matthew V., Climping, UNITED KINGDOM
 PI US 2004072734 A1 20040415
 AI US 2003-369143 A1 20030218 (10)
 RLI Division of Ser. No. US 2000-423578, filed on 23 Feb 2000, ABANDONED
 Continuation of Ser. No. WO 1998-EP3000, filed on 13 May 1998, UNKNOWN
 Continuation of Ser. No. US 1997-854943, filed on 13 May 1997, ABANDONED
 DT Utility
 FS APPLICATION
 LREP FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110
 CLMN Number of Claims: 35
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 1155
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention relates to a method of treating insulin resistance or Syndrome X. The method includes the step of administering a therapeutically effective amount of a somatostatin or a somatostatin agonist to said patient. The invention also includes pharmaceutical compositions comprising a somatostatin or somatostatin agonist and the use of such products in the preparation of such compositions.

L9 ANSWER 3 OF 6 USPATFULL on STN
 AN 2002:273372 USPATFULL
 TI METHOD AND COMPOSITIONS FOR TREATING HYPERLIPIDEMIA AND OTHER CONDITIONS
 IN CAWTHORNE, MICHAEL ANTHONY, WEST SUSSEX, UNITED KINGDOM
 LIU, YONG-LING, BUCKINGHAM, UNITED KINGDOM
 SENNITT, MATTHEW V., W. SUSSEX, UNITED KINGDOM
 PI US 2002151500 A1 20021017
 AI US 2000-423683 A1 20000320 (9)
 WO 1998-EP2998 19980513
 DT Utility
 FS APPLICATION
 LREP BRIAN R MORRILL, BIOMEASURE INC, 27 MAPLE STREET, MILFORD, MA, 01757-3650
 CLMN Number of Claims: 31

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 587

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method of treating hyperlipidemia and to reducing **triacylglycerols, glycerol** and **cholesterol** in a patient. The method includes the step of administering a therapeutically effective amount of a type-5 selective somatostatin agonist to said patient. A pharmaceutical composition comprises said agonist and such product is used in the preparation of the composition for use in treating hyperlipidemia or reducing **triacylglycerols, glycerol** and **cholesterol** in a patient's body.

L9 ANSWER 4 OF 6 USPATFULL on STN

AN 2002:251723 USPATFULL

TI Selective treatment of endothelial somatostatin receptors

IN Hsiang, York, Vancouver, CANADA

Buchan, Alison, Vancouver, CANADA

Levy, Julia G., Vancouver, CANADA

Margaron, Philippe Maria Clotaire, Burnaby, CANADA

PI US 2002137676 A1 20020926

AI US 2001-797779 A1 20010301 (9)

RLI Continuation-in-part of Ser. No. WO 1999-CA8800, filed on 1 Sep 1999, UNKNOWN

PRAI CA 1998-2246791 19980901

DT Utility

FS APPLICATION

LREP MORRISON & FOERSTER LLP, 3811 VALLEY CENTRE DRIVE, SUITE 500, SAN DIEGO, CA, 92130-2332

CLMN Number of Claims: 20

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 989

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides for the use of somatostatin receptor selective ligands (selective for SSTR1 or SSTR4) to treat human endothelial cells and to formulate medicaments for human use. The medicaments may for example be used to treat an angiogenic disease. In various embodiments, the angiogenic disease may for example be macular degeneration or a solid tumor. The SSTR1 or SSTR4 selective agonists may include the SSTR1 agonist (des-AA.sup.1,2,5 [DTrp.sup.8, IAamp.sup.9]SS).

L9 ANSWER 5 OF 6 USPATFULL on STN

AN 2002:78717 USPATFULL

TI METHOD OF TREATING INSULIN INSENSITIVITY AND SYNDROME X

IN CAWTHORNE, MICHAEL ANTHONY, HORSHAM, UNITED KINGDOM

LIU, YONG-LING, BUCKINGHAM, UNITED KINGDOM

SENNITT, MATTHEW V., CHIPSTEAD, UNITED KINGDOM

PI US 2002042374 A1 20020411

AI US 1998-76948 A1 19980513 (9)

PRAI US 1997-46373P 19970513 (60)

DT Utility

FS APPLICATION

LREP JOHN D CONWAY, BIOMEASURE INC, 27 MAPLE STREET, MILFORD, MA, 017573650

CLMN Number of Claims: 30

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1115

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method of treating insulin resistance or syndrome X in a patient. The method includes the step of administering a therapeutically effective amount of a somatostatin or a somatostatin agonist to said patient.

L9 ANSWER 6 OF 6 USPATFULL on STN
AN 1999:166969 USPATFULL
TI Method of treating hyperlipidemia
IN Cawthorne, Michael Anthony, Horsham, United Kingdom
Liu, Yong-Ling, Buckingham, United Kingdom
Sennitt, Matthew V., Chipstead, United Kingdom
PA Biomeasure, Incorporated, Milford, MA, United States (U.S. corporation)
PI US 6004928 19991221
AI US 1998-78111 19980513 (9)
PRAI US 1997-46346P 19970513 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Russel, Jeffrey E.
LREP Conway, John D.Fish & Richardson
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 584
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method of decreasing body weight in a patient. The method includes the step of administering a therapeutically effective amount of a type-5 selective somatostatin agonist to the patient.

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

STN INTERNATIONAL LOGOFF AT 17:25:19 ON 07 MAY 2004